Ambifect™ protein therapeutic platform
Akston has developed Ambifect™, a proprietary Fc-fusion platform to develop its therapeutic candidates. This versatile platform for multi-functional protein engineering supports tailored interaction with the immune system, delivery of customized agents for metabolic disease, and increased duration of action.
Features
- Proteins, such as Insulin and SARS-CoV-2 RBD, are selected to develop therapeutic candidates
- Fc region selected for species-specificity
- Saccharides enhance or suppress immune interaction
- Insulin mutations and c-peptide composition control insulin receptor activity
- Proprietary modifications reduce immunogenicity
- Linker moeity can be “tuned” for manufacturability
Candidate design and selection
Akston recognizes and identifies unmet needs in autoimmune disease, infectious disease, diabetes, and oncology, creates biologics to fulfill that need, and brings our products to the people who need them most.
Akston’s therapeutic designers make use of the Ambifect™ platform’s ability to specifically tailor the different components to optimize its performance and manufacturability. Bioactivity, half-life, interaction with the immune system, and other attributes may be affected by more than one component and how they are combined.
Typically, many candidates are synthesized and tested in vitro and in small animal models before larger quantities of fewer candidates are tested more thoroughly.
Once a group of promising candidates is found, variants can be designed, synthesized, and tested to optimize overall performance in a comparatively rapid and iterative process. This can significantly reduce development time and cost.
Manufacturing
Therapies developed using the Ambifect™ platform can be manufactured with the industry-standard techniques and equipment used for therapeutic antibody production.
Knowledge gained from the production of one therapeutic may be used for others. Each advance in manufacturing one candidate benefits the production of future candidates.
Akston has used the Ambifect™ platform to produce therapeutics that address a wide variety of disease conditions using the same production facility and analytical techniques.
.
